24 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
will, in the future, be successful in fully or even adequately hedging our currency risk.
Table of Contents
Risks Related to the Development of Our … the debt host agreement in accordance with ASC 815, Derivatives and Hedging. Accordingly, we recognized a derivative liability at fair value
424B7
OBSVF
ObsEva SA
3 Mar 22
Prospectus with selling stockholder info
4:43pm
, the selling shareholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the common shares … in the course of hedging in positions they assume. The selling shareholders may also sell common shares short and deliver common shares covered
F-3
OBSVF
ObsEva SA
17 Feb 22
Shelf registration (foreign)
4:14pm
. In connection with sales of the common shares or otherwise, the selling shareholders may enter into hedging transactions with broker-dealers, which … may in turn engage in short sales of the common shares in the course of hedging in positions they assume. The selling shareholders may also sell common
6-K
EX-99.3
OBSVF
ObsEva SA
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
and acknowledges that (y) one or more Purchasers may sell Conversion Shares or Warrant Shares or engage in hedging activities at various times during … the period that the Securities are outstanding and (z) such sales or hedging activities (if any) may negatively affect the Company’s stock price
424B7
d06wlqv709a6
23 Nov 21
Prospectus with selling stockholder info
4:06pm
F-3
qn8xph2bl k97revefb
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K/A
EX-99.2
vui47uqjk0b2e
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.5
l2i a841h71tc61uio
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.2
7fkf pqfh9w2m4hgn
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.5
32fc0
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
424B5
akwl6 60r
5 Mar 21
Prospectus supplement for primary offering
7:55am
424B5
04nlm4eflb6yqfs
8 Sep 20
Prospectus supplement for primary offering
7:31am
424B5
tk1xvw1
7 Aug 19
Prospectus supplement for primary offering
8:18am
6-K
EX-99.1
7648gx42qj h4nh2n1d
7 Aug 19
Current report (foreign)
7:21am
424B5
q3066pucut
20 Jun 18
Prospectus supplement for primary offering
5:32pm
424B5
sgitym lp8q
18 Jun 18
Prospectus supplement for primary offering
9:15pm